Clinical Profile of TB Patients on DOTS at a Tertiary Care Hospital
DOI:
https://doi.org/10.48165/jq3avw23Keywords:
TB patients, DOTS, HIVAbstract
Background: Tuberculosis was considered to be among the top ten causes of global mortality and morbidity. The highest incidence of TB was found in developing countries. Estimates suggest that 32% of the world‟s population was infected with TB. In India, it was seen that TB kills more adults than any other infectious disease. 20% global burden of TB was in India. Subjects and Methods: Before initiating anti tuberculosis treatment a detailed clinical assessment which included history and clinical examination was done. Hematological investigations like HIV test is done as per ICTC along with HBsAg. Hematological investigations included hemoglobin, WBC count, differential count, platelet count, prothrombin time and ESR. Biochemical investigations included total bilirubin, direct bilirubin, AST, ALT, alkaline phosphatase, random blood sugar, blood urea, s.creatinine and uric acid. Results: Out of the 50 patients studied, 70 % patients were sputum positive and 30 % were sputum negative. This is probably because majority of the patients studied were pulmonary tuberculosis. Conclusion: Adverse drug reaction was seen in 29 patients (58 %). One or more types of ADR was seen in these patients.
References
1. Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Tuberculosis Guide for Low Income Countries. 4th ed. International Union against Tuberculosis and Lung Disease 1996.
2. Murray CJ, Lopez AD. Mortality by Cause for Eight Regions of the World: Global Burden of Disease Study. Lancet 1997; 349 (9061): 1269-76
3. Murray CJ, Lopez AD. Regional Patterns of Disability Free Life
Expectancy and Disability – Adjusted Life Expectancy: Global Burden of Disease Study. Lancet 1997; 349 (9062): 1347 -52
4. World health organization. Global Tuberculosis control: Surveillance, Planning, Financing. WHO report 2005. Geneva: World Health Organisation, 2005
5. RNTCP status report DOTS for ALL, ALL for DOTS TB INDIA 2006, Central TB Division, Directorate General of Health Services MHFW New Delhi.
6. World Health Organization, International Union against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5:213-5.
7. Cantwell MF, Binkin NJ. Tuberculosis in Subsaharan Africa: A Regional Assessment of the Impact of the Human Immuno Deficiency Virus and National Tuberculosis Control Programme Quality. Tuber Lung Dis 1996; 77 (3): 220-5
8. RNTCP status report I am stopping TB, TB INDIA 2009 Central TB Division, Directorate General of Health Services MHFW New Delhi. 9. Treatment of Tuberculosis: Guidelines for National Programmes. 2nd ed. Geneva: World Health Organization, 1997.
10. Shashikant. Control of Tuberculosis. In: Sharma SK, Mohan, Tuberculosis. New Delhi: Jaypee Brothers 2004; 556-8.
11. Tripathi KD. Antitubercular drugs, Essentials of Medical Pharmacology. 5th ed. New delhi: Jaypee Brothers, 2003: 705-8.
12. Sharma H, Aqil M, Imam F, Alam MS, Kapur P, Pillai KK. A Pharmacovigilance Study in the Department Of Medicine of a University Teaching Hospital. Pharmacy Practice 2007; 5(1): 46-9.
